US Federal Circuit suspicious of Teva arguments in Orange Book patent delisting case
Teva Pharmaceuticals argued in front of the US Court of Appeals for the Federal Circuit that its inhaler patents should remain in the FDA's "Orange Book" despite not having explicit reference...To view the full article, register now.
Already a subscriber? Click here to view full article